About Summit

Our Mission:

Summit for Stem Cell Foundation’s mission is to support, educate and raise awareness about the development of today’s and tomorrow’s evidence-based regenerative medical therapies focused on Parkinson’s disease and other neurodegenerative disorders. It is our goal to empower patients and physicians with information to elevate their understanding in order to manage their care.

Our Vision

Summit for Stem Cell Foundation’s vision is a world where regenerative medicine is fully integrated into mainstream healthcare for persons with Parkinson’s disease and other neurological conditions as a treatment option.

  • Today, neurological disorders affect 1 billion worldwide. The fastest growing population is Parkinson’s disease. The latest estimated statistics:

    • In 1990 – 2.6 million, worldwide with Parkinson’s disease
    • Today – 10 million worldwide, diagnosed with Parkinson’s disease (more than doubling)
    • In 40 yrs., if left unchecked, the number of people diagnosed with Parkinson’s disease is expected to be 12.9+ million.
    •  Parkinson’s disease is projected to be the leading neurodegenerative disease – outpacing even Alzheimer’s disease.

These statistics need to change.

Summit History:

Summit for Stem Cell Foundation (Summit) began as a small group comprised of primarily Parkinson’s patients looking for a regenerative medicine (stem cell) treatment. The small group found and began raising funds to support Dr. Jeanne Loring’s and Dr. Andres Bratt-Leal’s efforts to address the symptoms of Parkinson’s disease through an autologous dopamine neuron replacement therapy.

Over time, the small group grew and is now an internationally recognized and supported 501(c)(3) organization. After a few years, Summit opened its own lab and, eventually, Drs. Loring and Bratt-Leal’s research project was successfully transferred to a newly founded company in the private sector in an effort to hasten the cell-based therapy’s path to FDA approved clinical trials. That company is “Aspen Neuroscience, Inc.” where Drs. Loring and Bratt-Leal remain involved guiding the project.

Today, Summit continues its primary focus on Parkinson’s disease due to our origins.

Sadly, the treatments and medications effectiveness currently in use is finite for neurodegenerative conditions. Summit believes the acquiescence of today’s symptomatic treatments and rescue medicines for life-altering ailments such as Parkinson’s disease is unacceptable.

Summit believes that regenerative medicine has the strongest potential to provide precision medical treatments to address illnesses and conditions affecting the nervous system. We feel that once Parkinson’s disease is adequately addressed by regenerative medicine, the “doors will open wide” for other neurogenerative conditions with unmet medical needs.

Summit, having launched a promising answer addressing the symptoms of Parkinson’s disease, dares to look outside the box at new and innovative regenerative medicine research. Summit continues its maverick approach looking for the answers to long-standing questions of:

“What is the CAUSE of Parkinson’s?”


“What is the CURE for Parkinson’s disease?”